Pemetrexed - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (4)Enzymes (2)

Targets (4)Enzymes (2)Biointeractions (5)

Identification

Name

Pemetrexed

Accession Number

DB00642 (APRD00573, EXPT02075)

Type

Small Molecule

Groups

Approved, Investigational

Description

Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Not Available

External IDs

LY-231514 / LY231514 / NSC-698037

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Pemetrexed disodium	2PKU919BA9	150399-23-8	NYDXNILOWQXUOF-GXKRWWSZSA-L	Details
Pemetrexed disodium hemipentahydrate	F4GSH45R4C	357166-30-4	ZCTCZKWJFTYNMZ-WKUCUCPSSA-J	Details
Pemetrexed disodium heptahydrate	9T47E4OM16	357166-29-1	QJVSMHJWAOSBMD-MYXYZBIASA-L	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Act Pemetrexed	Powder, for solution	500 mg	Intravenous	Actavis Pharma Company	Not applicable	Not applicable	Canada
Act Pemetrexed	Powder, for solution	1000 mg	Intravenous	Actavis Pharma Company	Not applicable	Not applicable	Canada
Act Pemetrexed	Powder, for solution	100 mg	Intravenous	Actavis Pharma Company	Not applicable	Not applicable	Canada
Alimta	Powder, for solution	500 mg	Intravenous	Eli Lilly & Co. Ltd.	2004-08-03	Not applicable	Canada
Alimta	Powder, for solution	100 mg	Intravenous	Eli Lilly & Co. Ltd.	2009-01-09	Not applicable	Canada
Alimta	Injection, powder, for solution	500 mg	Intravenous	Eli Lilly Nederland B.V.	2004-09-20	Not applicable	EU
Alimta	Injection, powder, for solution	100 mg	Intravenous	Eli Lilly Nederland B.V.	2004-09-20	Not applicable	EU
Pemetrexed	Powder, for solution	100 mg	Intravenous	Apotex Corporation	Not applicable	Not applicable	Canada
Pemetrexed	Powder, for solution	500 mg	Intravenous	Apotex Corporation	Not applicable	Not applicable	Canada
Pemetrexed Disodium for Injection	Powder, for solution	100 mg	Intravenous	Sandoz Canada Incorporated	Not applicable	Not applicable	Canada
Pemetrexed Disodium for Injection	Powder, for solution	500 mg	Intravenous	Teva	Not applicable	Not applicable	Canada
Pemetrexed Disodium for Injection	Powder, for solution	500 mg	Intravenous	Hospira, Inc.	Not applicable	Not applicable	Canada
Pemetrexed Disodium for Injection	Powder, for solution	100 mg	Intravenous	Accord Healthcare Limited	Not applicable	Not applicable	Canada
Pemetrexed Disodium for Injection	Powder, for solution	500 mg	Intravenous	Sandoz Canada Incorporated	Not applicable	Not applicable	Canada
Pemetrexed Disodium for Injection	Powder, for solution	100 mg	Intravenous	Teva	Not applicable	Not applicable	Canada
Pemetrexed Disodium for Injection	Powder, for solution	500 mg	Intravenous	Accord Healthcare Limited	Not applicable	Not applicable	Canada
Pemetrexed Disodium for Injection	Powder, for solution	1000 mg	Intravenous	Sandoz Canada Incorporated	Not applicable	Not applicable	Canada
Pemetrexed Disodium for Injection	Powder, for solution	100 mg	Intravenous	Hospira, Inc.	Not applicable	Not applicable	Canada
Pemetrexed Disodium for Injection	Powder, for solution	1000 mg	Intravenous	Hospira, Inc.	Not applicable	Not applicable	Canada
Taro-pemetrexed	Powder, for solution	500 mg	Intravenous	Taro Pharmaceuticals, Inc.	2017-02-15	Not applicable	Canada
Taro-pemetrexed	Powder, for solution	100 mg	Intravenous	Taro Pharmaceuticals, Inc.	Not applicable	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Ciambra	Injection, powder, for solution	100 mg	Intravenous	Menarini International Operations Luxembourg S.A.	2015-12-02	Not applicable	EU
Ciambra	Injection, powder, for solution	500 mg	Intravenous	Menarini International Operations Luxembourg S.A.	2015-12-02	Not applicable	EU
Pemetrexed Accord Solution for Infusion	Powder, for solution	1000 mg	Intravenous	Accord Healthcare Limited	2016-01-18	Not applicable	EU
Pemetrexed Hospira	Injection, powder, for solution	100 mg	Intravenous	Hospira, Inc.	2015-11-20	Not applicable	EU
Pemetrexed Hospira	Injection, powder, for solution	500 mg	Intravenous	Hospira, Inc.	2015-11-20	Not applicable	EU
Pemetrexed Hospira	Injection, powder, for solution	000 mg	Intravenous	Hospira, Inc.	2015-11-20	Not applicable	EU
Pemetrexed Lilly	Injection, powder, for solution	100 mg	Intravenous	Eli Lilly Netherlands	2015-09-14	Not applicable	EU
Pemetrexed Lilly	Injection, powder, for solution	500 mg	Intravenous	Eli Lilly Netherlands	2015-09-14	Not applicable	EU
Pemetrexed Medac	Injection, powder, for solution	100 mg	Intravenous	Medac Gesellschaft Für Klinische Spezialpräparate Mb H	2015-11-27	Not applicable	EU
Pemetrexed Medac	Injection, powder, for solution	500 mg	Intravenous	Medac Gesellschaft Für Klinische Spezialpräparate Mb H	2015-11-27	Not applicable	EU
Pemetrexed Medac	Injection, powder, for solution	1000 mg	Intravenous	Medac Gesellschaft Für Klinische Spezialpräparate Mb H	2015-11-27	Not applicable	EU
Pemetrexed Sandoz	Powder, for solution	1000 mg	Intravenous	Sandoz	2015-09-18	Not applicable	EU
Pemetrexed Sandoz	Injection, powder, for solution	500 mg	Intravenous	Sandoz	2015-09-18	Not applicable	EU
Pemetrexed Sandoz	Injection, powder, for solution	100 mg	Intravenous	Sandoz	2015-09-18	Not applicable	EU

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

04Q9AIZ7NO

CAS number

137281-23-3

Weight

Average: 427.4106
Monoisotopic: 427.149183429

Chemical Formula

C₂₀H₂₁N₅O₆

InChI Key

WBXPDJSOTKVWSJ-ZDUSSCGKSA-N

InChI

InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1

IUPAC Name

(2S)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioic acid

SMILES

[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O

Pharmacology

Indication

Used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy

Structured Indications

Pharmacodynamics

Preclinical studies have shown that pemetrexed inhibits the in vitro growth of mesothelioma cell lines (MSTO-211H, NCI-H2052). Studies with the MSTO-211H mesothelioma cell line showed synergistic effects when pemetrexed was combined concurrently with cisplatin.

Mechanism of action

Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Thymidylate synthase	Protein	yes	inhibitor	Human	P04818	details
Bifunctional purine biosynthesis protein PURH	Protein	yes	inhibitor	Human	P31939	details
Dihydrofolate reductase	Protein	yes	inhibitor	Human	P00374	details
Trifunctional purine biosynthetic protein adenosine-3	Protein	yes	inhibitor	Human	P22102	details

Absorption

Not Available

Volume of distribution

16.1 L

Protein binding

81%

Metabolism

Metabolized by Cytochrome P450 Enzymes

Route of elimination

Pemetrexed is not metabolized to an appreciable extent and is primarily eliminated in the urine, with 70% to 90% of the dose recovered unchanged within the first 24 hours following administration.

Half life

3.5 hours

Clearance

91.8 mL/min [Cancer patients with normal renal function receiving 0.2 to 838 mg/m2 infusion over a 10-minute period]

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Pemetrexed.	Approved
Bevacizumab	Bevacizumab may increase the cardiotoxic activities of Pemetrexed.	Approved, Investigational
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pemetrexed.	Approved
Clozapine	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Clozapine.	Approved
Cyclophosphamide	Cyclophosphamide may increase the cardiotoxic activities of Pemetrexed.	Approved, Investigational
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Pemetrexed.	Approved
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Pemetrexed.	Approved
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Pemetrexed.	Approved
Digoxin	Digoxin may decrease the cardiotoxic activities of Pemetrexed.	Approved
Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Pemetrexed.	Approved, Investigational
Fingolimod	Pemetrexed may increase the immunosuppressive activities of Fingolimod.	Approved, Investigational
G17DT	The risk or severity of adverse effects can be increased when Pemetrexed is combined with G17DT.	Investigational
INGN 201	The risk or severity of adverse effects can be increased when Pemetrexed is combined with INGN 201.	Investigational
INGN 225	The risk or severity of adverse effects can be increased when Pemetrexed is combined with INGN 225.	Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Leflunomide.	Approved, Investigational
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Pemetrexed.	Withdrawn
Natalizumab	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Natalizumab.	Approved, Investigational
Oleandrin	Anvirzel may decrease the cardiotoxic activities of Pemetrexed.	Experimental
Ouabain	Ouabain may decrease the cardiotoxic activities of Pemetrexed.	Approved
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pemetrexed.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pemetrexed.	Approved, Investigational
Rindopepimut	The risk or severity of adverse effects can be increased when Pemetrexed is combined with CDX-110.	Investigational
Roflumilast	Roflumilast may increase the immunosuppressive activities of Pemetrexed.	Approved
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pemetrexed.	Approved
SRP 299	The risk or severity of adverse effects can be increased when Pemetrexed is combined with SRP 299.	Investigational
Tacrolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pemetrexed.	Approved, Investigational
Tofacitinib	Pemetrexed may increase the immunosuppressive activities of Tofacitinib.	Approved, Investigational
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Pemetrexed.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

"DrugSyn.org":http://www.drugsyn.org/Pemetrexed.htm

US5344932

General References

Rollins KD, Lindley C: Pemetrexed: a multitargeted antifolate. Clin Ther. 2005 Sep;27(9):1343-82. [PubMed:16291410 ]
Lansiaux A, Lokiec F: [Pemetrexed: from preclinic to clinic]. Bull Cancer. 2007;94 Spec No Actualites:S134-8. [PubMed:17845983 ]
Fuld AD, Dragnev KH, Rigas JR: Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. doi: 10.1517/14656566.2010.482560. [PubMed:20446853 ]
Adjei AA: Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther. 2003 Apr;3(2):145-56. [PubMed:12722874 ]

External Links

Resource	Link
KEGG Drug	D07472
ChemSpider	393879
BindingDB	18796
ChEBI	63616
ChEMBL	CHEMBL225072
Therapeutic Targets Database	DCL000320
PharmGKB	PA10810
HET	LYA
Drug Product Database	13326
RxList	http://www.rxlist.com/cgi/generic3/alimta.htm
Drugs.com	http://www.drugs.com/cdi/pemetrexed.html
Wikipedia	Pemetrexed

ATC Codes

L01BA04

AHFS Codes

10:00.00

PDB Entries

1JU6

FDA label

Download (233 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Active Not Recruiting	Treatment	Brain and Central Nervous System Tumors / Chronic Myeloproliferative Disorders / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Metastatic Cancers / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous Conditions / Secondary Myelofibrosis / Unspecified Adult Solid Tumor, Protocol Specific	1
0	Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
1	Active Not Recruiting	Treatment	Adenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer	1
1	Active Not Recruiting	Treatment	Advanced Cancers	2
1	Active Not Recruiting	Treatment	Cancers	2
1	Active Not Recruiting	Treatment	Malignant Pleural Mesothelioma (MPM)	1
1	Active Not Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	3
1	Active Not Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC) / Tumors, Solid	1
1	Active Not Recruiting	Treatment	Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IV Non-Small Cell Lung Cancer	1
1	Active Not Recruiting	Treatment	Stage IV Non-Small Cell Lung Cancer	1
1	Active Not Recruiting	Treatment	Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Advanced Non-Small Cell Lung Cancer / Lung Cancer, Non-Small Cell	1
1	Completed	Treatment	Advanced Solid Tumors	1
1	Completed	Treatment	Advanced Solid Tumours / Cancers / Lung Cancer, Non-Small Cell	1
1	Completed	Treatment	Cancer, Advanced	2
1	Completed	Treatment	Cancer, Breast / Cancer, Ovarian / Esophageal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Prostate / Malignant Neoplasm of Stomach	1
1	Completed	Treatment	Cancer, Breast / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Prostate / Mesothelioma / Sarcomas	1
1	Completed	Treatment	Cancer, Ovarian / Cervical Cancers / Endometrial Cancers / Lung Cancers	1
1	Completed	Treatment	Cancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer	1
1	Completed	Treatment	Cancers	3
1	Completed	Treatment	Cancers / Metastases	1
1	Completed	Treatment	Carcinoma NOS / Lung Cancers / Non-Small Cell Lung	1
1	Completed	Treatment	Central Nervous System Lymphoma	1
1	Completed	Treatment	Esophageal Cancers	1
1	Completed	Treatment	Head and Neck Carcinoma	2
1	Completed	Treatment	Inoperable Non Small Cell Lung Cancer	1
1	Completed	Treatment	Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV	1
1	Completed	Treatment	Malignant Lymphomas / Tumors, Solid	1
1	Completed	Treatment	Mesothelioma	2
1	Completed	Treatment	Neoplasms	4
1	Completed	Treatment	Neoplasms, Malignant	1
1	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	6
1	Completed	Treatment	Non-Squamous Non-Small Cell Lung Cancer	1
1	Completed	Treatment	Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
1	Completed	Treatment	Solid Cancers	1
1	Completed	Treatment	Tumors, Solid	2
1	Completed	Treatment	Unspecified Adult Solid Tumor	1
1	Completed	Treatment	Unspecified Adult Solid Tumor, Protocol Specific	4
1	Completed	Treatment	Unspecified Childhood Solid Tumor, Protocol Specific	1
1	Not Yet Recruiting	Treatment	Carcinoma of the Lungs / Lungcancer	1
1	Not Yet Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
1	Recruiting	Other	Mesothelioma	1
1	Recruiting	Treatment	Advanced Malignancies / Cancer, Advanced	1
1	Recruiting	Treatment	Advanced Non-Small Cell Lung Cancer / KRAS Gene Mutation / Lung Cancers	1
1	Recruiting	Treatment	Advanced thymic carcinoma / Bladder Cancers / Cancer, Ovarian / Mesothelioma / Non-Small-Cell Lung Carcinoma (NSCLC) / Peritoneal Cancer / Thymus Cancer / Uterine Cervical Cancer	1
1	Recruiting	Treatment	Cancer, Advanced / Mesothelioma, Malignant / Metastatic Breast Cancer (MBC) / Metastatic Cancers / Non-Hodgkin's Lymphoma (NHL) / Non-Small-Cell Lung Carcinoma (NSCLC)	1
1	Recruiting	Treatment	Cancer, Breast / Colorectal Cancers / Esophagogastric Cancer / Malignant Neoplasm of Pancreas / Non-Small-Cell Lung Carcinoma (NSCLC) / Tumors	1
1	Recruiting	Treatment	Head and Neck Carcinoma / Salivary Gland Tumors	1
1	Recruiting	Treatment	Metastatic Malignant Neoplasm in the Brain / Stage IIIA Large Cell Lung Carcinoma / Stage IIIA Lung Adenocarcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Large Cell Lung Carcinoma / Stage IIIB Lung Adenocarcinoma / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Large Cell Lung Carcinoma / Stage IV Lung Adenocarcinoma / Stage IV Non-Small Cell Lung Cancer	1
1	Recruiting	Treatment	Neoplasms Metastasis / Neoplasms, Colorectal	1
1	Recruiting	Treatment	Non-Small Cell Lung Carcinoma (NSCLC)	1
1	Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	2
1	Recruiting	Treatment	Oncology, Medical	1
1	Recruiting	Treatment	Pleural Mesotheliomas	1
1	Recruiting	Treatment	Stage IV Lung Adenocarcinoma	1
1	Terminated	Treatment	Advanced Solid Malignancies / Cancers / Tumors, Solid	1
1	Terminated	Treatment	Malignant Lymphomas	1
1	Terminated	Treatment	Malignant Neoplasm of Pancreas	1
1	Terminated	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	3
1	Terminated	Treatment	Nonsmall Cell Lung Cancer Stage III / Nonsquamous Nonsmall Cell Neoplasm of Lung	1
1	Withdrawn	Treatment	Advanced Solid Tumors	1
1	Withdrawn	Treatment	Cancers / Neoplasms / Tumors	1
1	Withdrawn	Treatment	Lung Cancers	1
1	Withdrawn	Treatment	Malignant Pleural Mesothelioma (MPM)	1
1	Withdrawn	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
1, 2	Active Not Recruiting	Treatment	Advanced Malignant Mesothelioma / Epithelioid Mesothelioma / Pleural Malignant Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatoid Mesothelioma	1
1, 2	Active Not Recruiting	Treatment	Malignant Pleural Mesothelioma (MPM) / Non-Small-Cell Lung Carcinoma (NSCLC)	1
1, 2	Active Not Recruiting	Treatment	Non-Small Cell Lung Carcinoma (NSCLC)	1
1, 2	Active Not Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
1, 2	Completed	Treatment	Advanced Carcinoma / Non-Small-Cell Lung Carcinoma (NSCLC)	1
1, 2	Completed	Treatment	Cancer, Advanced / Non-Small-Cell Lung Carcinoma (NSCLC)	1
1, 2	Completed	Treatment	Cancer, Breast	1
1, 2	Completed	Treatment	Cancer, Ovarian / Primary Peritoneal Cancer	1
1, 2	Completed	Treatment	Colorectal Cancers	1
1, 2	Completed	Treatment	Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer	1
1, 2	Completed	Treatment	Lung Cancers / Non-Small-Cell Lung Cancer (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC)	1
1, 2	Completed	Treatment	Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific	2
1, 2	Completed	Treatment	Malignant Pleural Mesothelioma (MPM)	1
1, 2	Completed	Treatment	Malignant Pleural Mesothelioma (MPM) / Tumors, Solid	1
1, 2	Completed	Treatment	Malignant Pleural Mesotherioma	1
1, 2	Completed	Treatment	Neoplasm, Gastric	1
1, 2	Completed	Treatment	Neoplasms, Lung	1
1, 2	Completed	Treatment	Non-Small Cell Lung Carcinoma (NSCLC)	1
1, 2	Completed	Treatment	Non-Small-Cell Lung Cancer (NSCLC)	1
1, 2	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	6
1, 2	Completed	Treatment	Rectal Carcinoma	1
1, 2	Completed	Treatment	Transitional Cell Carcinoma	1
1, 2	Completed	Treatment	Urologic Neoplasms	1
1, 2	Recruiting	Treatment	Advanced Malignant Solid Neoplasm / Advanced Peritoneal Malignant Mesothelioma / Advanced Pleural Malignant Mesothelioma / Advanced thymic carcinoma / Neoplasms, Advanced Solid / Recurrent Malignant Solid Neoplasm / Recurrent Peritoneal Malignant Mesothelioma / Recurrent Pleural Malignant Mesothelioma / Recurrent Solid Neoplasm / Solid Neoplasms / Stage III Non-Small Cell Lung Cancer / Stage III Ovarian Cancer / Stage III Pleural Mesothelioma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Ovarian Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IIIB Ovarian Cancer / Stage IIIC Ovarian Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Cancer / Stage IV Pleural Mesothelioma / Unresectable Solid Neoplasm	1
1, 2	Recruiting	Treatment	Advanced or Metastatic Colorectal Cancer (CRC) / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor / Advanced or Metastatic Solid Tumors / Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous) / Pancreatic Ductal Adenocarcinoma (PDAC)	1
1, 2	Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	2
1, 2	Recruiting	Treatment	To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy	1
1, 2	Terminated	Treatment	Cancer, Breast / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific	1
1, 2	Terminated	Treatment	Carcinoma, Small Cell / Lung Cancer Small Cell Lung Cancer (SCLC)	1
1, 2	Terminated	Treatment	Head and Neck Carcinoma	1
1, 2	Terminated	Treatment	Mesothelioma	1
1, 2	Terminated	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	3
1, 2	Unknown Status	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	2
1, 2	Withdrawn	Treatment	Malignant Pleural Mesothelioma (MPM)	1
2	Active Not Recruiting	Treatment	Brain and Central Nervous System Tumors / Malignant Lymphomas / Metastatic Cancers	1
2	Active Not Recruiting	Treatment	Lung Cancers	4
2	Active Not Recruiting	Treatment	Lung Cancers / Neoplasms Metastasis	1
2	Active Not Recruiting	Treatment	Malignant Pleural Mesothelioma (MPM)	1
2	Active Not Recruiting	Treatment	Mesothelioma, Malignant	2
2	Active Not Recruiting	Treatment	Metastatic Breast Cancer (MBC)	1
2	Active Not Recruiting	Treatment	Metastatic Non-Small Cell Lung Cancer / Nonsquamous Nonsmall Cell Neoplasm of Lung	1
2	Active Not Recruiting	Treatment	Non Small Cell Lung Carcinoma (NSCLC)	1
2	Active Not Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	5
2	Active Not Recruiting	Treatment	Nonsquamous Nonsmall Cell Neoplasm of Lung	1
2	Active Not Recruiting	Treatment	Recurrent Non-small Cell Lung Cancer / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
2	Approved for Marketing	Not Available	Mesothelioma	1
2	Completed	Not Available	Metastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB / Nonsquamous Non-Small Cell Neoplasm of Lung	1
2	Completed	Diagnostic	Cancers	1
2	Completed	Prevention	Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy	1
2	Completed	Treatment	Adenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease	1
2	Completed	Treatment	Adenocarcinoma of the Lung	1
2	Completed	Treatment	Adenocarcinoma of the Lung / Metastatic Brain Tumors	1
2	Completed	Treatment	Adenocarcinomas	1
2	Completed	Treatment	Adenocarcinomas / Non-Small-Cell Lung Cancer (NSCLC)	1
2	Completed	Treatment	Advanced Gastric Carcinoma	1
2	Completed	Treatment	Advanced Non Small Cell Lung Cancer (NSCLC)	1
2	Completed	Treatment	Advanced Non-Small Cell Lung Cancer	1
2	Completed	Treatment	Advanced Non-Squamous Non-Small Cell Lung Cancer	1
2	Completed	Treatment	Bladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer	1
2	Completed	Treatment	Breast Neoplasms, Male / Cancer, Breast / Ductal Carcinoma	1
2	Completed	Treatment	Cancer of the Endometrium / Endometrial Cancers / Endometrial Carcinoma / Endometrium Cancer / Genital Neoplasms, Female / Genitourinary tract neoplasm / Neoplasms / Neoplasms by Site / Neoplasms, Endometrial / Uterine Neoplasms	1
2	Completed	Treatment	Cancer, Breast	6
2	Completed	Treatment	Cancer, Breast / Neoplasms Metastasis	1
2	Completed	Treatment	Cancer, Breast / Neoplasms, Breast	1
2	Completed	Treatment	Cancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cancer	1
2	Completed	Treatment	Cancer, Ovarian / Peritoneal Cancer	1
2	Completed	Treatment	Cancer, Ovarian / Primary Peritoneal Cavity Cancer	1
2	Completed	Treatment	Cancers	1
2	Completed	Treatment	Carcinoma NOS / Non-Small-Cell Lung Carcinoma (NSCLC)	1
2	Completed	Treatment	Carcinoma, Small Cell	1
2	Completed	Treatment	Cervical Cancers	2
2	Completed	Treatment	Cervical Intraepithelial Neoplasia (CIN) / Genital Neoplasms, Female / Uterine Neoplasms	1
2	Completed	Treatment	Choriocarcinoma / Hydatidiform Mole / Trophoblastic Neoplasms / Uterine Neoplasms	1
2	Completed	Treatment	Colorectal Cancers	2
2	Completed	Treatment	Endometrial Cancers	1
2	Completed	Treatment	Ependymomas / Ewing's Sarcoma (ES) / Medulloblastomas / Neuroblastoma (Measurable Disease) / Neuroblastoma (Metaiodobenzylguanidine / Non-brainstem High-grade Glioma / Positive Evaluable) / Rhabdomyosarcomas / Sarcoma, Osteogenic	1
2	Completed	Treatment	Head and Neck Carcinoma	4
2	Completed	Treatment	Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer	1
2	Completed	Treatment	Liver Cancer	1
2	Completed	Treatment	Lung Cancer, Non-Small Cell	1
2	Completed	Treatment	Lung Cancers	20
2	Completed	Treatment	Lung Cancers / Metastatic Cancers	1
2	Completed	Treatment	Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC)	1
2	Completed	Treatment	Lung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)	2
2	Completed	Treatment	Malignant Neoplasm of Pancreas	1
2	Completed	Treatment	Malignant Neoplasm of Prostate	1
2	Completed	Treatment	Malignant Neoplasm of Stomach	2
2	Completed	Treatment	Malignant Pleural Mesothelioma (MPM)	2
2	Completed	Treatment	Mesothelioma	4
2	Completed	Treatment	Mesothelioma, Malignant	2
2	Completed	Treatment	Mesothelioma / Neoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC)	1
2	Completed	Treatment	Metastatic Colorectal Cancers	2
2	Completed	Treatment	Metastatic Non-squamous Non Small Cell Lung Cancer	1
2	Completed	Treatment	Nasopharyngeal Neoplasms	1
2	Completed	Treatment	Neoplasm Metastases / Urologic Neoplasms	1
2	Completed	Treatment	Neoplasms, Breast	1
2	Completed	Treatment	Neoplasms, Gastrointestinal	1
2	Completed	Treatment	Neoplasms, Head and Neck	2
2	Completed	Treatment	Neoplasms, Lung	1
2	Completed	Treatment	Neoplasms, Ovarian / Primary Peritoneal Cancer	1
2	Completed	Treatment	Neuroendocrine Tumors	1
2	Completed	Treatment	Non-Small Cell Lung Carcinoma (NSCLC)	1
2	Completed	Treatment	Non-Small-Cell Lung Cancer (NSCLC)	5
2	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	32
2	Completed	Treatment	Non-Squamous Non-Small Cell Lung Cancer	2
2	Completed	Treatment	Ovarian Carcinoma / Primary Peritoneal Carcinoma	1
2	Completed	Treatment	Pleural Neoplasms	1
2	Completed	Treatment	Previous Treated Metastatic Non-small Cell Lung Cancer	1
2	Completed	Treatment	Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer	1
2	Completed	Treatment	Rectal Neoplasms	1
2	Completed	Treatment	Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma	1
2	Completed	Treatment	Recurrent Non-small Cell Lung Cancer	1
2	Completed	Treatment	Sarcoma, Osteogenic	1
2	Completed	Treatment	Sarcomas	2
2	Completed	Treatment	Soft Tissue Sarcoma (STS)	1
2	Completed	Treatment	Advanced thymic carcinoma / Thymic Carcinoma	1
2	Completed	Treatment	Transitional Cell Carcinoma	1
2	Completed	Treatment	Urologic Neoplasms	1
2	Not Yet Recruiting	Treatment	Adenocarcinoma of the Lung	1
2	Not Yet Recruiting	Treatment	Advanced Non-squamous Non-small-cell Lung Cancer	1
2	Not Yet Recruiting	Treatment	Colo-rectal Cancer	1
2	Not Yet Recruiting	Treatment	EGFR Gene Mutations / Nonsmall Cell Lung Cancer	1
2	Not Yet Recruiting	Treatment	Malignant Pleural Mesothelioma (MPM)	1
2	Not Yet Recruiting	Treatment	Metastatic Brain Tumors	1
2	Not Yet Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	3
2	Recruiting	Diagnostic	Stage IIIA Non-Small Cell Lung Cancer	1
2	Recruiting	Treatment	Adenocarcinoma of the Cervix / Adenosquamous Cell Carcinoma of the Cervix	1
2	Recruiting	Treatment	Adenocarcinoma of the Lung	1
2	Recruiting	Treatment	Adenocarcinoma of the Lung / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
2	Recruiting	Treatment	Adenocarcinomas / Carcinoma, Large Cell / Heregulin / Non-Small-Cell Lung Carcinoma (NSCLC) / Squamous Cell Carcinoma (SCC)	1
2	Recruiting	Treatment	Adenocarcinomas / Neoplasms, Lung	1
2	Recruiting	Treatment	Advanced NSCLC	1
2	Recruiting	Treatment	Advanced Stage IIIB / High Thymidylate Synthase Expression / Non-Small-Cell Lung Carcinoma (NSCLC) / Secondary	1
2	Recruiting	Treatment	Bevacizumab / Metastatic Brain Tumors / Non Squamous Non-small Cell Lung Cancer	1
2	Recruiting	Treatment	Bladder Cancers / Urothelial Cancer	1
2	Recruiting	Treatment	Cancer, Breast / Metastatic Breast Cancer (MBC) / Recurrent Breast Cancer	1
2	Recruiting	Treatment	Cancers	1
2	Recruiting	Treatment	Carcinoma, Non-squamous Non-small-cell Lung	1
2	Recruiting	Treatment	Colorectal Cancers	1
2	Recruiting	Treatment	EGFR Mutations / Metastatic Brain Tumors / Non-Small-Cell Lung Carcinoma (NSCLC)	1
2	Recruiting	Treatment	Lung Cancers	2
2	Recruiting	Treatment	Malignant Pleural Mesothelioma (MPM)	1
2	Recruiting	Treatment	Medulloblastomas	1
2	Recruiting	Treatment	Mesothelioma	2
2	Recruiting	Treatment	Metastatic Colorectal Cancers	1
2	Recruiting	Treatment	Metastatic Non-Small Cell Lung Cancer	1
2	Recruiting	Treatment	Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)	1
2	Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	9
2	Recruiting	Treatment	Non-small-cell Lung Cancer With Somatic EGFR Mutations	1
2	Recruiting	Treatment	Squamous Cell Carcinoma of Lung	1
2	Recruiting	Treatment	Stage IV Non-Small Cell Lung Cancer	1
2	Suspended	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
2	Terminated	Diagnostic	Malignant Pleural Mesothelioma (MPM) / Pleural Mesotheliomas	1
2	Terminated	Treatment	Cancer, Ovarian / Peritoneal Cancer	1
2	Terminated	Treatment	Carcinoma, Small Cell	1
2	Terminated	Treatment	Esophageal Cancers	1
2	Terminated	Treatment	Gestational Trophoblastic Disease	1
2	Terminated	Treatment	Head and Neck Carcinoma	1
2	Terminated	Treatment	Lung Cancer - Non Small Cell	1
2	Terminated	Treatment	Lung Cancer Small Cell Lung Cancer (SCLC)	4
2	Terminated	Treatment	Lung Cancers	6
2	Terminated	Treatment	Malignant Neoplasm of Pancreas	1
2	Terminated	Treatment	Mesothelioma, Malignant	1
2	Terminated	Treatment	Mesothelioma / Pleural Mesotheliomas	1
2	Terminated	Treatment	Metastatic Colorectal Cancers	1
2	Terminated	Treatment	Neoplasms, Esophageal	1
2	Terminated	Treatment	Neoplasms, Lung	1
2	Terminated	Treatment	Non Small Cell Lung Carcinoma (NSCLC)	1
2	Terminated	Treatment	Non-Small Cell Lung Carcinoma (NSCLC)	2
2	Terminated	Treatment	Non-Small-Cell Lung Cancer (NSCLC)	3
2	Terminated	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	9
2	Terminated	Treatment	Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer / Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer	1
2	Terminated	Treatment	Recurrent Non Small Cell Lung Cancer	1
2	Terminated	Treatment	Recurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
2	Terminated	Treatment	Renal Cell Adenocarcinoma	1
2	Unknown Status	Treatment	Advanced Non-Small Cell Lung Cancer	1
2	Unknown Status	Treatment	Malignant / Mesothelioma / Pleural	1
2	Unknown Status	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	8
2	Unknown Status	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC) / Toxicity	1
2	Unknown Status	Treatment	Pleural Mesotheliomas	1
2	Unknown Status	Treatment	Squamous Cell Carcinoma of Head and Neck	1
2	Unknown Status	Treatment	Thyroid Cancers	1
2	Unknown Status	Treatment	Tumors, Central Nervous System	1
2	Unknown Status	Treatment	Untreated Advanced Non-Small Cell Lung Cancer	1
2	Withdrawn	Treatment	Advanced Malignant Mesothelioma / Epithelial Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma	1
2	Withdrawn	Treatment	Cancer of Head and Neck	1
2	Withdrawn	Treatment	Esophagogastric Cancer	1
2	Withdrawn	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
2	Withdrawn	Treatment	Primary Central Nervous System Lymphoma (PCNSL)	1
2	Withdrawn	Treatment	Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
2	Withdrawn	Treatment	Stage III Non-Small Cell Lung Cancer	1
2, 3	Active Not Recruiting	Treatment	Non-Small Cell Lung Cancer Recurrent / Non-Small-Cell Lung Carcinoma (NSCLC) / Progression of Non-small Cell Lung Cancer	1
2, 3	Completed	Treatment	Mesothelioma	1
2, 3	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
2, 3	Not Yet Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
2, 3	Recruiting	Treatment	Mesothelioma	1
2, 3	Terminated	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
3	Active Not Recruiting	Prevention	Non-Small-Cell Lung Carcinoma (NSCLC)	1
3	Active Not Recruiting	Treatment	Adenocarcinomas / Non-Small-Cell Lung Carcinoma (NSCLC)	1
3	Active Not Recruiting	Treatment	Advanced Non Small Cell Lung Cancer	1
3	Active Not Recruiting	Treatment	Advanced Non-Small Cell Lung Cancer	1
3	Active Not Recruiting	Treatment	Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC)	1
3	Active Not Recruiting	Treatment	Lung Cancers	2
3	Active Not Recruiting	Treatment	Lung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)	1
3	Active Not Recruiting	Treatment	Metastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB	1
3	Active Not Recruiting	Treatment	NSCLC (Non-Small Cell Lung Cancer)	1
3	Active Not Recruiting	Treatment	Non Small Cell Lung Cancer (Squamous or Non Squamous)	1
3	Active Not Recruiting	Treatment	Non-Small Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC)	1
3	Active Not Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	7
3	Active Not Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma NSCLC	1
3	Active Not Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer	1
3	Active Not Recruiting	Treatment	Non-Squamous Non-Small Cell Lung Cancer	1
3	Active Not Recruiting	Treatment	Stage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer	1
3	Active Not Recruiting	Treatment	Stage IV or Recurrent Non-Small Cell Lung Cancer	1
3	Completed	Treatment	Lung Cancer Small Cell Lung Cancer (SCLC)	1
3	Completed	Treatment	Lung Cancers	1
3	Completed	Treatment	Mesothelioma	1
3	Completed	Treatment	Mesothelioma, Malignant	1
3	Completed	Treatment	Neoplasm Metastases / Neoplasms, Pancreatic	1
3	Completed	Treatment	Neoplasms, Head and Neck	1
3	Completed	Treatment	Non Small Cell Lung Carcinoma (NSCLC)	2
3	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	14
3	Completed	Treatment	Non-Squamous Non-Small Cell Lung Cancer	3
3	Enrolling by Invitation	Treatment	Cancers	1
3	Enrolling by Invitation	Treatment	EGFR Gene Mutations	1
3	Not Yet Recruiting	Treatment	Carcinoma, Bronchogenic / Chronic Lung Diseases / Neoplasm, Bronchial / Neoplasms by Site / Neoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC) / Respiratory Tract Diseases / Respiratory Tract Neoplasms / Thoracic Neoplasms	1
3	Not Yet Recruiting	Treatment	Carcinoma，Non-Small-Cell Lung / Lung Carcinomas, Non-Small-Cell / Non-Small-Cell Lung Carcinoma (NSCLC) / Nonsmall Cell Lung Cancer	1
3	Not Yet Recruiting	Treatment	Malignant Hydrothorax / Non-Small-Cell Lung Carcinoma (NSCLC)	1
3	Not Yet Recruiting	Treatment	Non-Small-Cell Lung Cancer (NSCLC)	1
3	Not Yet Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	2
3	Recruiting	Not Available	Adenocarcinoma of Lung Metastatic to Brain / Bevacizumab / Brain Radiotherapy / Cerebral Metastases / Cerebral Radiotherapy / Metastatic Non-Small Cell Lung Cancer / Non Epidermoid / Non-Small-Cell Lung Carcinoma (NSCLC)	1
3	Recruiting	Treatment	Carcinoma，Non-Small-Cell Lung	1
3	Recruiting	Treatment	Chemotherapeutic Toxicity / Chemotherapy Effect / Stomach Neoplasms	1
3	Recruiting	Treatment	First Line Non-Small Cell Lung Cancer	1
3	Recruiting	Treatment	Mesothelioma	2
3	Recruiting	Treatment	Metastatic Non-Squamous Non-Small Cell Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC)	1
3	Recruiting	Treatment	Neoplasms, Lung	1
3	Recruiting	Treatment	Non Small Cell Lung Carcinoma (NSCLC) / Non Small Cell Lung Carcinoma NSCLC	2
3	Recruiting	Treatment	Non-Small Cell Lung Carcinoma (NSCLC)	1
3	Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	6
3	Recruiting	Treatment	Non-Squamous Non-Small Cell Lung Cancer / Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer	1
3	Recruiting	Treatment	Oligo-metastatic Stage IV Non-small Cell Lung Cancer / Oligo-metastatic Stage IV Non-small Cell Lung Cancer（NSCLC）	1
3	Terminated	Treatment	Lung Cancers / Neoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC) / Pulmonary Neoplasms	1
3	Terminated	Treatment	Non Small Cell Lung Carcinoma (NSCLC)	1
3	Terminated	Treatment	Recurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
3	Unknown Status	Treatment	Lung Cancers	1
3	Unknown Status	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
3	Unknown Status	Treatment	Non-squamous Nonsmall Cell Neoplasm of Lung	1
4	Completed	Treatment	Locally Advanced Malignant Neoplasm	1
4	Completed	Treatment	Non-Small-Cell Lung Cancer (NSCLC)	1
4	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	2
4	Not Yet Recruiting	Treatment	Adenocarcinoma of the Lung	1
4	Recruiting	Treatment	Adenocarcinoma of the Lung	1
4	Recruiting	Treatment	Adenocarcinomas / EGFR Positive Non-small Cell Lung Cancer	2
4	Recruiting	Treatment	Non-Small-Cell Lung Cancer (NSCLC)	1
Not Available	Completed	Not Available	Neoplasms, Lung	1
Not Available	Completed	Not Available	Non-Small-Cell Lung Carcinoma (NSCLC)	1
Not Available	Completed	Treatment	Hypermethylation / Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC)	1
Not Available	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
Not Available	Terminated	Treatment	Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
Not Available	Unknown Status	Screening	Non-Small-Cell Lung Carcinoma (NSCLC)	1
Not Available	Unknown Status	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1

Pharmacoeconomics

Manufacturers

Eli lilly and co

Packagers

Eli Lilly & Co.

Dosage forms

Form	Route	Strength
Powder, for solution	Intravenous	100 mg
Powder, for solution	Intravenous	500 mg
Injection, powder, for solution	Intravenous	100 mg
Injection, powder, for solution	Intravenous	500 mg
Powder, for solution	Intravenous	1000 mg
Injection, powder, for solution	Intravenous	000 mg
Injection, powder, for solution	Intravenous	1000 mg

Prices

Unit description	Cost	Unit
Alimta 500 mg Solution Vial	3154.94USD	vial
Alimta 500 mg vial	3033.6USD	vial
Alimta 100 mg vial	606.72USD	vial

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA1340794	No	1999-10-19	2016-10-19	Canada
CA2400155	No	2009-09-15	2021-02-12	Canada
US5217974	No	1994-03-29	2011-03-29	US
US5344932	Yes	1997-01-24	2017-01-24	US
US7772209	Yes	2002-05-24	2022-05-24	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
logP	-1.5	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0905 mg/mL	ALOGPS
logP	-0.19	ALOGPS
logP	-0.25	ChemAxon
logS	-3.7	ALOGPS
pKa (Strongest Acidic)	3.34	ChemAxon
pKa (Strongest Basic)	7.13	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	9	ChemAxon
Hydrogen Donor Count	7	ChemAxon
Polar Surface Area	187.96 Å²	ChemAxon
Rotatable Bond Count	9	ChemAxon
Refractivity	120.46 m³·mol^-1	ChemAxon
Polarizability	43.06 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.6997
Blood Brain Barrier	+	0.7542
Caco-2 permeable	-	0.819
P-glycoprotein substrate	Substrate	0.5
P-glycoprotein inhibitor I	Non-inhibitor	0.9729
P-glycoprotein inhibitor II	Non-inhibitor	0.9825
Renal organic cation transporter	Non-inhibitor	0.8923
CYP450 2C9 substrate	Non-substrate	0.7547
CYP450 2D6 substrate	Non-substrate	0.8204
CYP450 3A4 substrate	Non-substrate	0.6051
CYP450 1A2 substrate	Non-inhibitor	0.912
CYP450 2C9 inhibitor	Non-inhibitor	0.8938
CYP450 2D6 inhibitor	Non-inhibitor	0.9117
CYP450 2C19 inhibitor	Non-inhibitor	0.8844
CYP450 3A4 inhibitor	Non-inhibitor	0.8253
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9508
Ames test	Non AMES toxic	0.8528
Carcinogenicity	Non-carcinogens	0.964
Biodegradation	Not ready biodegradable	0.8296
Rat acute toxicity	2.5023 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9624
hERG inhibition (predictor II)	Non-inhibitor	0.8718

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Glutamic acid and derivatives

Alternative Parents

N-acyl-alpha amino acids / Hippuric acids / Pyrrolo[2,3-d]pyrimidines / Benzoyl derivatives / Pyrimidones / Aminopyrimidines and derivatives / Substituted pyrroles / Dicarboxylic acids and derivatives / Vinylogous amides / Heteroaromatic compounds

Substituents

Glutamic acid or derivatives / Hippuric acid or derivatives / Hippuric acid / N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / Pyrrolopyrimidine / Benzamide / Pyrrolo[2,3-d]pyrimidine / Benzoic acid or derivatives / Benzoyl

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

pyrrolopyrimidine, N-acyl-L-glutamic acid (CHEBI:63616 )

Targets

Details

1. Thymidylate synthase

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Thymidylate synthase activity
Specific Function:: Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Gene Name:: TYMS
Uniprot ID:: P04818
Molecular Weight:: 35715.65 Da

References

Adjei AA: Gemcitabine and Pemetrexed disodium in treating breast cancer. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7. [PubMed:11252887 ]
Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73. [PubMed:11524555 ]
Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55. [PubMed:11531245 ]
Adjei AA: Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer. 2001 Dec;34 Suppl 4:S103-5. [PubMed:11742712 ]
Norman P: Pemetrexed disodium (Eli Lilly). Curr Opin Investig Drugs. 2001 Nov;2(11):1611-22. [PubMed:11763166 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Schultz RM, Dempsey JA: Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 2001 Sep-Oct;21(5):3209-14. [PubMed:11848474 ]
Adjei AA: Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3. [PubMed:12023793 ]
Molina JR, Adjei AA: The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer. 2003 Jul;5(1):21-7. [PubMed:14596699 ]
Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28. [PubMed:15795320 ]
Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. [PubMed:12571811 ]

Details

2. Bifunctional purine biosynthesis protein PURH

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Protein homodimerization activity
Specific Function:: Bifunctional enzyme that catalyzes 2 steps in purine biosynthesis.Promotes insulin receptor/INSR autophosphorylation and is involved in INSR internalization (PubMed:25687571).
Gene Name:: ATIC
Uniprot ID:: P31939
Molecular Weight:: 64615.255 Da

References

Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. [PubMed:12571811 ]
Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73. [PubMed:11524555 ]
Racanelli AC, Rothbart SB, Heyer CL, Moran RG: Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009 Jul 1;69(13):5467-74. doi: 10.1158/0008-5472.CAN-08-4979. Epub 2009 Jun 23. [PubMed:19549896 ]

Details

3. Dihydrofolate reductase

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Nadph binding
Specific Function:: Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.
Gene Name:: DHFR
Uniprot ID:: P00374
Molecular Weight:: 21452.61 Da

References

Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73. [PubMed:11524555 ]
Norman P: Pemetrexed disodium (Eli Lilly). Curr Opin Investig Drugs. 2001 Nov;2(11):1611-22. [PubMed:11763166 ]
Mauritz R, Peters GJ, Priest DG, Assaraf YG, Drori S, Kathmann I, Noordhuis P, Bunni MA, Rosowsky A, Schornagel JH, Pinedo HM, Jansen G: Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol. 2002 Jan 15;63(2):105-15. [PubMed:11841783 ]
Schultz RM, Dempsey JA: Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 2001 Sep-Oct;21(5):3209-14. [PubMed:11848474 ]
Adjei AA: Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3. [PubMed:12023793 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Adjei AA: Gemcitabine and Pemetrexed disodium in treating breast cancer. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7. [PubMed:11252887 ]
Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55. [PubMed:11531245 ]
Adjei AA: Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer. 2001 Dec;34 Suppl 4:S103-5. [PubMed:11742712 ]
Molina JR, Adjei AA: The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer. 2003 Jul;5(1):21-7. [PubMed:14596699 ]
Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28. [PubMed:15795320 ]
Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. [PubMed:12571811 ]

Details

4. Trifunctional purine biosynthetic protein adenosine-3

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Phosphoribosylglycinamide formyltransferase activity
Specific Function:: Not Available
Gene Name:: GART
Uniprot ID:: P22102
Molecular Weight:: 107766.295 Da

References

Schultz RM, Dempsey JA: Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 2001 Sep-Oct;21(5):3209-14. [PubMed:11848474 ]
Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73. [PubMed:11524555 ]
Molina JR, Adjei AA: The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer. 2003 Jul;5(1):21-7. [PubMed:14596699 ]
Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28. [PubMed:15795320 ]
Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. [PubMed:12571811 ]
Adjei AA: Gemcitabine and Pemetrexed disodium in treating breast cancer. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7. [PubMed:11252887 ]
Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55. [PubMed:11531245 ]
Adjei AA: Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer. 2001 Dec;34 Suppl 4:S103-5. [PubMed:11742712 ]
Adjei AA: Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3. [PubMed:12023793 ]
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Details

1. Deoxycytidine kinase

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inducer

General Function:: Protein homodimerization activity
Specific Function:: Required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA). Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents.
Gene Name:: DCK
Uniprot ID:: P27707
Molecular Weight:: 30518.315 Da

References

De Pas TM, Toffalorio F, Giovannetti E, Radice D, Russo F, Angeli I, Calamai G, Spitaleri G, Catania C, Noberasco C, Milani A, Pelosi G, Danesi R, De Braud F: Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. J Thorac Oncol. 2011 Apr;6(4):768-73. doi: 10.1097/JTO.0b013e31820d7818. [PubMed:21336182 ]

Details

2. Equilibrative nucleoside transporter 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inducer

General Function:: Nucleoside transmembrane transporter activity
Specific Function:: Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs).
Gene Name:: SLC29A1
Uniprot ID:: Q99808
Molecular Weight:: 50218.805 Da

References

De Pas TM, Toffalorio F, Giovannetti E, Radice D, Russo F, Angeli I, Calamai G, Spitaleri G, Catania C, Noberasco C, Milani A, Pelosi G, Danesi R, De Braud F: Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. J Thorac Oncol. 2011 Apr;6(4):768-73. doi: 10.1097/JTO.0b013e31820d7818. [PubMed:21336182 ]

Drug created on June 13, 2005 07:24 / Updated on June 24, 2017 13:11

Get DrugBank to go!

Structure for DB00642 (Pemetrexed)

Targets

References

References

References

References

Enzymes

References

References